[
  {
    "ts": null,
    "headline": "5 Must-Read Analyst Questions From Baxter’s Q1 Earnings Call",
    "summary": "Baxter’s first quarter saw revenue and adjusted profit both exceed Wall Street expectations, but the market responded cautiously to the results. Management attributed the quarter’s performance to strong execution in Medical Products & Therapies as well as Healthcare Systems & Technologies, highlighting robust demand for infusion systems and progress in stabilizing IV solutions supply after earlier disruptions. Interim CEO Brent Shafer noted, “Our results reflect the building momentum of our stra",
    "url": "https://finnhub.io/api/news?id=a373a9fcbdf1cf4869e6c1e96fabff5f5ccf3cfd8931d8103e31be83a80eebe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750924118,
      "headline": "5 Must-Read Analyst Questions From Baxter’s Q1 Earnings Call",
      "id": 135558320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BAX",
      "source": "Yahoo",
      "summary": "Baxter’s first quarter saw revenue and adjusted profit both exceed Wall Street expectations, but the market responded cautiously to the results. Management attributed the quarter’s performance to strong execution in Medical Products & Therapies as well as Healthcare Systems & Technologies, highlighting robust demand for infusion systems and progress in stabilizing IV solutions supply after earlier disruptions. Interim CEO Brent Shafer noted, “Our results reflect the building momentum of our stra",
      "url": "https://finnhub.io/api/news?id=a373a9fcbdf1cf4869e6c1e96fabff5f5ccf3cfd8931d8103e31be83a80eebe5"
    }
  }
]